MedTrace Logo

Reduction of Cancer Related Fatigue in Patients During TKI Therapy

NCT01645150 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-03-22

No results posted yet for this study

Summary

The purpose of this pilot study is to determine the effects of a 12-week resistance training program on cancer related fatigue in cancer patients receiving tyrosine kinase inhibitor (TKI) therapy. It is hypothesized that incidence and severity of cancer related fatigue can be reduced by exercise training in this population which leads to an improved treatment completion rate.

Conditions

  • All Tumor Entities Treated With TKI Therapy

Interventions

BEHAVIORAL

Progressive strength training

12 weeks of supervised progressive strength training

Sponsors & Collaborators

  • German Cancer Research Center

    lead OTHER

Principal Investigators

  • Carsten Grüllich, MD · National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany

  • Friederike Scharhag-Rosenberger, PhD · National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany

  • Joachim Wiskamann, PhD · National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany

  • Dirk Jäger, Professor · National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany

  • Karen Steindorf, Professor · National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01645150 on ClinicalTrials.gov